CTCL clinical trials at UCSF
1 research study open to new patients
A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors
open to eligible people ages 18-99
To evaluate MEDI9197 when administered by intratumoral injection to subjects with solid tumors or CTCL, and in combination with durvalumab and/or palliative radiation in subjects with solid tumors.
San Francisco, California and other locations